967 / 1084
A meta-analysis of
first-line chemotherapy versus best support care
studies reported a hazard ratio
(HR) of 0.39 (95% CI, 0.28 to 0.52;
P
.001) for OS in favor of chemotherapy, translating to
a benefit in
weighted median average survival of approximately 6 months
03/28/2017